Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776298 | 0.91 | RHOA (0.39) | RHOABRAFCA2CA9 | |
| SCHEMBL16776437 | 0.91 | RHOA (0.43) | RHOABRAFFYNCA2CA9 | |
| SCHEMBL16776024 | 0.89 | IMPDH2 (0.46) | RHOABRAFCA9BRD4CREBBP | |
| SCHEMBL16776322 | 0.89 | NPC1 (0.44) | BRAFFYNCA2CA9KIT | |
| SCHEMBL16776358 | 0.88 | HTR2C (0.48) | BRAFFYNKITHTR2AHTR2C | |
| SCHEMBL16776329 | 0.87 | FYN (0.42) | BRAFFYNCA2CA9GPR142 | |
| SCHEMBL16775995 | 0.87 | BRAF (0.41) | BRAFLIMK2NPC1 | |
| SCHEMBL16776450 | 0.87 | RHOA (0.49) | RHOABRD4CREBBPKITGPR142 | |
| SCHEMBL16776321 | 0.87 | FYN (0.44) | BRAFFYNCA2CA9KIT | |
| SCHEMBL16776297 | 0.87 | RHOA (0.37) | RHOABRAFFYNCA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RHOA 4798/4885BRAF 3419/4885FYN 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.